Patients with severe asthma may be eligible for both mepolizumab and omalizumab. Evidence of the relative effectiveness of these treatments would be informative. Treatment effectiveness was examined via an indirect treatment comparison. Exacerbation rates, lung function and tolerability profiles were broadly comparable. Mepolizumab seems to be at least as effective as omalizumab in severe asthma.